What's Happening?
Quebec has become the first Canadian province to publicly reimburse Jemperli (dostarlimab for injection) in combination with chemotherapy for treating adult patients with primary advanced or first recurrent endometrial cancer. This decision, announced
by GSK, marks a significant milestone in improving access to treatment for eligible patients. The reimbursement is facilitated through the Régie de l'assurance maladie du Québec (RAMQ), removing financial barriers and enabling timely access to this standard-of-care combination therapy. The decision follows Health Canada's approval of the indication in April 2025, based on the RUBY phase III trial results, which demonstrated significant survival benefits. This move is expected to set a positive precedent for other provinces in Canada.
Why It's Important?
The public reimbursement of Jemperli plus chemotherapy in Quebec is crucial as it addresses a significant care gap for patients with advanced or recurrent endometrial cancer. Historically, outcomes for such patients treated with chemotherapy alone have been poor, with median overall survival often less than three years. By expanding access to this evidence-based treatment, Quebec is enhancing the quality of life and survival prospects for patients. This decision also highlights the importance of government support in making advanced cancer treatments accessible, potentially influencing other provinces to follow suit. The move aligns with broader efforts to improve cancer care and patient outcomes across Canada.
What's Next?
Following Quebec's lead, there may be increased pressure on other Canadian provinces to adopt similar reimbursement policies for Jemperli plus chemotherapy. GSK has expressed its commitment to collaborating with other jurisdictions to ensure rapid access to this treatment for all eligible Canadian patients. The success of this initiative in Quebec could prompt further negotiations with the pan-Canadian Pharmaceutical Alliance and other healthcare stakeholders to expand access nationwide. Additionally, ongoing monitoring of patient outcomes and further research could provide more data to support the efficacy and benefits of this treatment combination.
